

**ATONCO AND GIP ARRONAX SIGN CONTRACT TO DEVELOP AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY**

**Saint-Herblain, France  
April 15th, 2024**

Atonco and GIP ARRONAX (Saint Herblain, France) have joined forces to take the next step in the implementation of alpha-immunotherapy for cancer. Their partnership aims to develop and validate the radiopharmaceutical production process under GMP (Good Manufacturing Practice) conditions for Atonco's ATO-101 (Girentuximab radiolabeled with astatine-211), with a view to clinical intravesical instillation for the treatment of non-musculo-invasive bladder cancer. Through this collaboration, two players in Nantes' radiopharmaceutical industry are combining their expertise: the development of innovative radiopharmaceuticals using astatine-211 (Atonco) and the production of radionuclides and radiopharmaceuticals for nuclear medicine research (GIP ARRONAX).

This collaboration represents a key step in the transfer to the clinic of astatine-211, an alpha particle emitting radionuclide enabling the selective destruction of targeted tumor cells. It builds on the astatine-211 production expertise developed within GIP ARRONAX, and follows on from the radiochemistry research work carried out in Nantes by CRCI<sup>2</sup>NA team 2, which led to the development of radiolabeling and control methods for astatine-211-labeled Girentuximab. As part of this partnership with Atonco, GIP ARRONAX plays a key role in the pharmaceutical development and validation of manufacturing processes and control methods under GMP conditions, in preparation for the production of validation batches with a view to the first human clinical trials.

Laurette Fisson, Atonco's CMC and Product Development Director: *"This collaboration reinforces Atonco's position as a leader in the development of innovative astatine-211-based radiopharmaceuticals, contributing to the advancement of targeted therapeutic options for patients with cancers resistant to standard therapies. We are delighted to collaborate with GIP ARRONAX, a long-standing partner with recognized expertise in radiopharmaceutical research and development."*

Férid Haddad, Director of GIP ARRONAX: *"This collaboration with Atonco is the culmination of nearly 15 years' work by GIP ARRONAX on astatine-211, a promising alpha emitter. We are proud to contribute to the progress of nuclear medicine, and particularly to the development of alpha radiotherapy, a therapeutic solution with a future."*

**About Atonco:**

Atonco is a private company developing targeted radiopharmaceuticals for oncology applications. Atonco and its partners, who have emerged from the nuclear medicine cluster in Nantes, are committed to the clinical use of alpha-emitting radionuclides, in particular astatine-211.

For more information, visit [www.atonco-pharma.com](http://www.atonco-pharma.com)

**About GIP ARRONAX :**

ARRONAX is a grouping of several public and private-sector members carrying out public-interest missions in the fields of research, economic development and training. It has a high-energy, high-intensity multi-particle cyclotron for the production of non-conventional radionuclides, including astatine-211, of which it is one of two European producers. GIP ARRONAX manufactures radiopharmaceuticals to GMP/GMP standards to support early-stage clinical research.

For more information, visit <https://www.aronax-nantes.fr/gip-aronax/>

**Contacts :**

- Tony Prézeau, Director Technology Transfer and Partnerships, GIP ARRONAX  
[prezeau@aronax-nantes.fr](mailto:prezeau@aronax-nantes.fr)
- Sylvain Fanier, President, Atonco  
[sylvain.fanier@atonco-pharma.com](mailto:sylvain.fanier@atonco-pharma.com)